Haisco Pharmaceutical (002653.SZ) Receives Approval for New Indication of Innovative Drug HSK39297 Tablets in Clinical Trials

Stock News

Yesterday

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) announced that it recently received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration. After review, the clinical trial application for HSK39297 tablets, submitted in August 2025, met the relevant requirements for drug registration, and approval was granted to proceed with clinical trials.

HSK39297 tablets are a novel, independently developed drug with proprietary intellectual property rights for treating age-related macular degeneration (AMD). Preclinical research results indicate that the drug has a clear target, proven efficacy, and favorable safety, making it a highly promising small-molecule drug. With a high benefit/risk ratio and broad clinical application prospects, HSK39297 tablets are expected to become an effective treatment for AMD, addressing the current shortage of clinical therapies for this condition.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1158005608"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1158005608\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1158005608?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 15:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158005608","market":"sg","top_or_hot":-1,"title":"Haisco Pharmaceutical (002653.SZ) Receives Approval for New Indication of Innovative Drug HSK39297 Tablets in Clinical Trials","media":"Stock News","content":"<p>Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) announced that it recently received the \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration. After review, the clinical trial application for HSK39297 tablets, submitted in August 2025, met the relevant requirements for drug registration, and approval was granted to proceed with clinical trials.</p>\n<p>HSK39297 tablets are a novel, independently developed drug with proprietary intellectual property rights for treating age-related macular degeneration (AMD). Preclinical research results indicate that the drug has a clear target, proven efficacy, and favorable safety, making it a highly promising small-molecule drug. With a high benefit/risk ratio and broad clinical application prospects, HSK39297 tablets are expected to become an effective treatment for AMD, addressing the current shortage of clinical therapies for this condition.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Haisco Pharmaceutical (002653.SZ) Receives Approval for New Indication of Innovative Drug HSK39297 Tablets in Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHaisco Pharmaceutical (002653.SZ) Receives Approval for New Indication of Innovative Drug HSK39297 Tablets in Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-13 15:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) announced that it recently received the \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration. After review, the clinical trial application for HSK39297 tablets, submitted in August 2025, met the relevant requirements for drug registration, and approval was granted to proceed with clinical trials.</p>\n<p>HSK39297 tablets are a novel, independently developed drug with proprietary intellectual property rights for treating age-related macular degeneration (AMD). Preclinical research results indicate that the drug has a clear target, proven efficacy, and favorable safety, making it a highly promising small-molecule drug. With a high benefit/risk ratio and broad clinical application prospects, HSK39297 tablets are expected to become an effective treatment for AMD, addressing the current shortage of clinical therapies for this condition.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002653","symbol_name":"海思科","start_time":0,"source_url":"","article_id":"1158005608","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158005608","pubTimestamp":1763020091,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) announced that it recently received the \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration. After review, the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","002653":"海思科","BK0028":"国家队","06978":"永泰生物-B","BK0077":"质押式回购","BK0239":"医药制造","BK0188":"融资融券","BK1161":"生物科技","BK1574":"生物医药B类股","BK0033":"西藏振兴"},"translate_title":"海思科制药（002653.SZ）创新药HSK39297片新适应症临床试验获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"002653":1,"06978":1},"content_text":"Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) announced that it recently received the \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration. After review, the clinical trial application for HSK39297 tablets, submitted in August 2025, met the relevant requirements for drug registration, and approval was granted to proceed with clinical trials.\nHSK39297 tablets are a novel, independently developed drug with proprietary intellectual property rights for treating age-related macular degeneration (AMD). Preclinical research results indicate that the drug has a clear target, proven efficacy, and favorable safety, making it a highly promising small-molecule drug. With a high benefit/risk ratio and broad clinical application prospects, HSK39297 tablets are expected to become an effective treatment for AMD, addressing the current shortage of clinical therapies for this condition.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}